In a previous study from our group, it was demonstrated that mTOR inhibitors inhibit cell proliferation in H295R and SW13 human ACC cell lines, but in H295R, probably as consequence of the IGF2 overexpression, this treatment could activate two potential pathways of escape to treatment with traditional mTOR inhibitors, i.e. the AKT and ERK pathways [25]. Here, MTOR is linked to adrenal cortex carcinoma.